The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
accepted:
04
02
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
aheadofprint
Résumé
The European Union (EU) regulatory network was at the forefront of the safety monitoring of COVID-19 vaccines during the pandemic. An unprecedented number of case reports of suspected adverse reactions after vaccination called for huge efforts for the assessment of this safety information, to ensure that any possible risks were detected and managed as early as possible, while ruling out coincidental but temporally related adverse health outcomes. We describe the role of the European Medicines Agency alongside the EU regulatory network in the safety monitoring of the COVID-19 vaccines, and provide an insight into challenges, particularities and outcomes of the scientific assessment and regulatory decisions in the complex, dynamic international environment of the pandemic. We discuss the flexible procedural tools that were used to ensure an expedited scientific assessment of safety issues, and subsequent updates of the product information (i.e., labelling) when available evidence (e.g., spontaneous reports, findings from observational studies and/or scientific literature) suggested that causal association is at least a reasonable possibility. The safety monitoring was accompanied by enhanced transparency measures, proactive communication, and easy access to information, which played a key role in public reassurance. The pandemic has been a powerful booster for worldwide collaboration, exchange of information and work-sharing. The safety monitoring of COVID-19 vaccines continues, and the lessons learned will be applied in future safety reviews, as well as future health emergencies.
Identifiants
pubmed: 38396269
doi: 10.1007/s40264-024-01405-9
pii: 10.1007/s40264-024-01405-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Coronavirus disease (COVID-19) pandemic. https://www.who.int/europe/emergencies/situations/covid-19 . Accessed 4 Aug 2023.
COVID-19: European Medicines Regulatory Network’s Response to the Pandemic. https://www.ema.europa.eu/en/annual-report-2020/covid-19-european-medicines-regulatory-networks-response-pandemic.html . Accessed 4 Aug 2023.
European Medicines Agency. Emergency Task Force. https://www.ema.europa.eu/en/committees/working-parties-other-groups/emergency-task-force-etf . Accessed 1 Oct 2023.
European Medicines Agency. Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines. https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines_en.pdf Accessed 8 Aug 2023.
EudraVigilance - European database of suspected adverse drug reaction reports. https://www.adrreports.eu/en/index.html . Accessed 17 Aug 2023.
Pharmacovigilance Risk Assessment Committee, Rules of Procedure https://www.ema.europa.eu/en/documents/other/prac-rules-procedure_en.pdf . Accessed 4 Aug 2023.
European Medicines Agency. Report on pharmacovigilance tasks. From EU Member States and the European Medicines Agency (EMA) 2019–2022. https://www.ema.europa.eu/en/documents/report/report-pharmacovigilance-tasks-eu-member-states-european-medicines-agency-ema-2019-2022_en.pdf . Accessed 17 Aug 2023.
European Medicines Agency. Consideration on core requirements for PSURs of COVID-19 vaccines. https://www.ema.europa.eu/en/documents/scientific-guideline/consideration-core-requirements-psurs-covid-19-vaccines_en.pdf . Accessed 22 Aug 2023.
European Medicines Agency. Consideration on core requirements for RMPs of COVID19 vaccines. https://www.ema.europa.eu/en/documents/other/consideration-core-requirements-rmps-covid-19-vaccines_en.pdf . Accessed 22 Aug 2023.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module IX—Signal management (Rev 1). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf . Accessed 8 Aug 2023.
Durand J, Dogné J-M, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, et al. Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther. 2023;113:1223–34. https://doi.org/10.1002/cpt.2828 .
doi: 10.1002/cpt.2828
pubmed: 36524423
Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic Cohort study of 23 million residents. JAMA Cardiology. 2022;7:600–12. https://doi.org/10.1001/jamacardio.2022.0583 .
doi: 10.1001/jamacardio.2022.0583
pubmed: 35442390
pmcid: 9021987
EPI-PHARE. Myocardite et péricardite après la vaccination Covid-19. https://www.epi-phare.fr/rapports-detudes-et-publications/myocardite-pericardite-vaccination-covid19-12-50ans/ . Accessed 22 Aug 2023.
European Medicines Agency: COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-preliminary-view-suggests-no-specific-issue-batch-used-austria#:~:text=The%20Austrian%20national%20competent%20authority,vaccination%2C%20and%20another%20was%20hospitalised . Accessed 12 Sept 2023.
European Medicines Agency. Referral procedures. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures-human-medicines#:~:text=In%20a%20referral%2C%20the%20European,the%20European%20Union%20(EU ). Accessed 1 Oct 2023.
European Medicines Agency. Assessment report. Procedure under Article 5(3) of Regulation (EC) No 726/2004. https://www.ema.europa.eu/en/documents/referral/use-vaxzevria-prevent-covid-19-article-53-procedure-assessment-report_en.pdf . Accessed 1 Oct 2023.
Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–9. https://doi.org/10.1056/NEJMoa2109730 .
doi: 10.1056/NEJMoa2109730
pubmed: 34614328
Goddard K, Lewis N, Fireman B, Weintraub E, Shimabukuro T, Zerbo O, et al. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022;40:5153–9. https://doi.org/10.1016/j.vaccine.2022.07.007 .
doi: 10.1016/j.vaccine.2022.07.007
pubmed: 35902278
pmcid: 9273527
EU PAS Register. https://www.encepp.eu/encepp/viewResource.htm?id=50610 . Accessed 1 Oct 2023.
EU PAS Register. https://www.encepp.eu/encepp/viewResource.htm?id=50716 . Accessed 1 Oct 2023.
Rudolph A, Savage DR. Vulval aphthous ulcers in adolescents following COVID-19 vaccination-analysis of an international case series. J Pediatr Adolesc Gynecol. 2023. https://doi.org/10.1016/j.jpag.2023.03.006 .
doi: 10.1016/j.jpag.2023.03.006
pubmed: 36934803
pmcid: 10020135
Damiani G, Pacifico A, Pelloni F, Iorizzo M. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? J Eur Acad Dermatol Venereol. 2021;35:e645–7. https://doi.org/10.1111/jdv.17472 .
doi: 10.1111/jdv.17472
pubmed: 34169578
pmcid: 8447358
Schmidt V, Blum R, Möhrenschlager M. Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy. J Eur Acad Dermatol Venereol. 2022;36:e88-90. https://doi.org/10.1111/jdv.17722 .
doi: 10.1111/jdv.17722
pubmed: 34606112
European Medicines Agency. Spikevax: Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf . Accessed 3 Aug 2023.
European Medicines Agency. Comirnaty: summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf . Accessed 3 Aug 2023.
Petruzzi M, Galleggiante S, Messina S, Della VF. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases. BMC Oral Health. 2022;22:90. https://doi.org/10.1186/s12903-022-02124-2 .
doi: 10.1186/s12903-022-02124-2
pubmed: 35331228
pmcid: 8943505
Charfi O, Lakhoua G, Berrim K, Kastalli S, Aouinti I, Badri T, et al. Erythema multiforme reactions following Pfizer/BioNTech (tozinameran) vaccination: two case-reports with positive rechallenge and review of the literature. Curr Drug Saf. 2023. https://doi.org/10.2174/1574886318666230725101846 .
doi: 10.2174/1574886318666230725101846
pubmed: 37489779
Spikevax: procedural steps taken and scientific information after the authorization. < https://www.ema.europa.eu/en/documents/procedural-steps-after/spikevax-previously-covid-19-vaccine-moderna-epar-procedural-steps-taken-scientific-information_en.pdf . Accessed 8 Aug 2023.
European Medicines Agency. Screening for adverse reactions in EudraVigilance. https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf . Accessed 1 Oct 2023.
Bijwerkingen Centrum Lareb. https://www.lareb.nl/media/dxcjbjmv/signals_2022_covid19-vaccines-and-menstrual-disorders_update.pdf . Accessed 8 Aug 2023.
Agence nationale de sécurité du médicament et des produits de santé. Menstrual disturbances following COVID-19 vaccination - current knowledge and advice for the concerned women. 2022. https://ansm.sante.fr/actualites/troubles-menstruels-apres-la-vaccination-contre-le-covid-19-etat-des-connaissances-et-conseils-aux-femmes-concernees . Accessed 8 Aug 2023.
Trogstad, Lill. Increased occurrence of menstrual disturbances in 18- to 30-year-old women after COVID-19 vaccination (January 1, 2022). Available at SSRN: https://ssrn.com/abstract=3998180 or https://doi.org/10.2139/ssrn.3998180 .
Trogstad L, Laake I, Robertson AH, Mjaaland S, Caspersen IH, Juvet LK, et al. Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination. Vaccine. 2023;41:5271–82. https://doi.org/10.1016/j.vaccine.2023.06.088 .
doi: 10.1016/j.vaccine.2023.06.088
pubmed: 37451876
Nguyen BT, Pang RD, Nelson AL, Pearson JT, Benhar Noccioli E, Reissner HR, et al. Detecting variations in ovulation and menstruation during the COVID-19 pandemic, using real-world mobile app data. PLoS ONE. 2021;16: e0258314. https://doi.org/10.1371/journal.pone.0258314 .
doi: 10.1371/journal.pone.0258314
pubmed: 34669726
pmcid: 8528316
Edelman A, Boniface ER, Benhar E, Han L, Matteson KA, Favaro C, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. Obstet Gynecol. 2022;139:481–9. https://doi.org/10.1097/AOG.0000000000004695 .
doi: 10.1097/AOG.0000000000004695
pubmed: 34991109
pmcid: 8936155
Gibson EA, Li H, Fruh V, Gabra M, Asokan G, Jukic AMZ, et al. Covid-19 vaccination and menstrual cycle length in the Apple Women’s Health Study. NPJ Digit Med. 2022;5:165. https://doi.org/10.1038/s41746-022-00711-9 .
doi: 10.1038/s41746-022-00711-9
pubmed: 36323769
pmcid: 9628464
European Medicines Agency. Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. https://www.ema.europa.eu/en/news/vaxzevria-ema-advises-against-use-people-history-capillary-leak-syndrome . Accessed 12 Dec 2023.
de Chambrun MP, Moyon Q, Faguer S, Urbanski G, Mathian A, Zucman N, et al. The consequences of COVID-19 pandemic on patients with monoclonal gammopathy-associated systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol Pract. 2022;10:626–9. https://doi.org/10.1016/j.jaip.2021.11.023 .
doi: 10.1016/j.jaip.2021.11.023
Busin M, Zauli G, Pellegrini M, Virgili G, Yu AC. COVID-19 vaccination may not increase rates of corneal graft rejection. Cornea. 2022;41:1536–8. https://doi.org/10.1097/ICO.0000000000003101 .
doi: 10.1097/ICO.0000000000003101
pubmed: 35965396
Bizimungu C, Sabbe M, Wuillaume F, Hamdani J, Koch P, Dogné J-M. Challenges in assessing COVID-19 vaccines safety signals—the case of ChAdOx1 nCoV-19 vaccine and corneal graft rejection. Vaccines (Basel). 2023. https://doi.org/10.3390/vaccines11050954 .
doi: 10.3390/vaccines11050954
pubmed: 37243058
Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28:410–22. https://doi.org/10.1038/s41591-021-01630-0 .
doi: 10.1038/s41591-021-01630-0
pubmed: 34907393
Prieto-Alhambra D. Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-COV-2. EUPAS40414. https://www.encepp.eu/encepp/viewResource.htm?id=43976 . Accessed 8 Aug 2023.
Abbasi J. Researchers investigate what COVID-19 does to the heart. JAMA. 2021;325:808–11. https://doi.org/10.1001/jama.2021.0107 .
doi: 10.1001/jama.2021.0107
pubmed: 33566089
American Academy of Pediatrics, Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/ . Accessed 8 Aug 2023.
Saito Y, Suwa Y, Kaneko Y, Tsujiwaki M, Odagawa Y. Kikuchi-Fujimoto disease following COVID-19 infection in a 7-year-old girl: a case report and literature review. Cureus. 2022;14: e26540. https://doi.org/10.7759/cureus.26540 .
doi: 10.7759/cureus.26540
pubmed: 35936128
pmcid: 9351715
Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation 2 of immunization safety data. https://brightoncollaboration.us/wp-content/uploads/2021/11/Myocarditis-and-Pericarditis-manuscript_validated.pdf . Accessed 17 Aug 2023.
What’s New MedDRA Version 24.1. https://admin.meddra.org/sites/default/files/guidance/file/000636_whatsnew_24_1.pdf . Accessed 8 Aug 2023.
Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215–22. https://doi.org/10.1002/pds.3918 .
doi: 10.1002/pds.3918
pubmed: 26602179
Willame C, Dodd C, Durán CE, Elbers R, Gini R, Bartolini C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases—an ACCESS cohort study. Vaccine. 2023;41:251–62. https://doi.org/10.1016/j.vaccine.2022.11.031 .
doi: 10.1016/j.vaccine.2022.11.031
pubmed: 36446653
Toolbox. Dashboard Background rates of Adverse Events of Special Interest for COVID-19 vaccines. https://vac4eu.org/covid-19-tool/ . Accessed 17 Aug 2023.
Karlsson TS, Marions LB, Edlund MG. Heavy menstrual bleeding significantly affects quality of life. Acta Obstet Gynecol Scand. 2014;93:52–7. https://doi.org/10.1111/aogs.12292 .
doi: 10.1111/aogs.12292
pubmed: 24266506
Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ. 2022;379: e071594. https://doi.org/10.1136/bmj-2022-071594 .
doi: 10.1136/bmj-2022-071594
pubmed: 36288813
pmcid: 9597610
Bots SH, Riera-Arnau J, Belitser SV, Messina D, Aragón M, Alsina E, et al. Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: a population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries. Front Pharmacol. 2022;13:1038043. https://doi.org/10.3389/fphar.2022.1038043 .
doi: 10.3389/fphar.2022.1038043
pubmed: 36506571
pmcid: 9730238
Safety Signal—Assessment of responses to Request for Supplementary Information (RSI). https://www.ema.europa.eu/en/documents/other/timetable-safety-signal-assessment-responses-request-supplementary-information-rsi_en.pdf . Accessed 07 Aug 2023.
European Medicines Agency. 2021 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission. https://www.ema.europa.eu/en/documents/report/2021-annual-report-eudravigilance-european-parliament-council-commission_en.pdf . Accessed 1 Oct 2023.
European Medicines Agency. Referral. https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots_en.pdf . Accessed 12 Dec 2023.
European Medicines Agency. Variations for human medicines. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/variations-human-medicines . Accessed 22 Aug 2023.
European Medicines Agency. Transparency: exceptional measures for COVID-19 medicines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-public-health-emergency-international-concern-2020-23/transparency-exceptional-measures-covid-19-medicines . Accessed 17 Aug 2023.
COVID-19 important messages. EudraVigilance—European database of suspected adverse reaction reports. https://www.adrreports.eu/en/covid19_message.html . Accessed 17 Aug 2023.
European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant])—Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines). https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant_en.pdf . Accessed 10 Oct 2023.
European Medicines Agency. Signal assessment report on myocarditis/pericarditis with Comirnaty. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-myocarditis-pericarditis-tozinameran-covid-19-mrna-vaccine_en.pdf . Accessed 1 Oct 2023.
European Medicines Agency. Signal assessment report on myocarditis/pericarditis with Spikevax. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-myocarditis-pericarditis-spikevax-previously-covid-19-vaccine-moderna-covid_en.pdf . Accessed 1 Oct 2023.
European Medicines Agency. Signal assessment report on heavy menstrual bleeding and Spikevax. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-heavy-menstrual-bleeding-covid-19-mrna-vaccine-spikevax_en.pdf . Accessed 1 Oct 2023.
European Medicines Agency. Signal assessment report on heavy menstrual bleeding with Comirnaty. https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-heavy-menstrual-bleeding-tozinameran/comirnaty-covid-19-mrna-vaccine_en.pdf . Accessed 1 Oct 2023.
European Medicines Agency. Comirnaty. Periodic safety update report assessment 19 December 2021 to 18 June 2022. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/comirnaty-periodic-safety-update-report-assessment-19-december-2021-18-june-2022_en.pdf-0 . Accessed 12 Dec 2023.
European Medicines Agency. EMA regular press briefing on public health emergencies. https://www.ema.europa.eu/en/events/ema-regular-press-briefing-public-health-emergencies-0 . Accessed 17 Aug 2023.
European Medicines Agency. COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy. https://www.ema.europa.eu/en/news/covid-19-latest-safety-data-provide-reassurance-about-use-mrna-vaccines-during-pregnancy . Accessed 22 Aug 2023.
European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood . Accessed 17 Aug 2023
European Health Union. https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/promoting-our-european-way-life/european-health-union_en . Accessed 14 Sept 2023.
International Coalition of Medicines Regulatory Authorities (ICMRA). https://icmra.info/drupal/en . Accessed 17 Aug 2023.
European Medicines Agency. International Agreements. https://www.ema.europa.eu/en/partners-networks/international-activities/international-agreements . Accessed 17 Aug 2023.
European Medicines Agency, Heads of Medicines Agencies. COVID-19 lessons learned. Joint report on the response to the Public Health Emergency. https://www.ema.europa.eu/en/documents/report/covid-19-lessons-learned-joint-report-response-public-health-emergency_en.pdf . Accessed 12 Dec 2023.